MNK News 85.34 09/04/2014 05:15:38 Mallinckrodt Plc Ordinary

New Post Public Reply Private Reply Replies (0) Message Board

Sep 4, 2014 at 6:15 AM

Mallinckrodt Plc Ordinary Share (MNK) 85.34 $MNK

Merck KGaA in Deal with S-TARget, Allergy Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:50PM CDT
Merck KGaA's (MKGAF) Allergopharma, strikes deal with S-TARget therapeutics for developing a new generation of therapies for allergies using S-TIR technology.

Novo Nordisk Drops Anti-Inflammatory R&D Activities - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:20PM CDT
Novo Nordisk (NVO) intends to ramp up its efforts to strengthen its core business area - diabetes prevention and treatment, obesity and diabetes complications.

Stocks End Mixed; Mallinckrodt Clears Buy Point
at Investor's Business Daily - Wed Sep 03, 4:03PM CDT
Stocks ended mixed Wednesday, with the Dow Jones industrial average edging higher and the Nasdaq erasing all of the previous day's gains amid a sell-off in Apple (AAPL) . The Dow edged up 0.1% but the Nasdaq fell 0.6% and the S&P 500 slipped 0.1%....

Drug M&A Boom Driven By Long-Term Trends: PwC
at Investor's Business Daily - Wed Sep 03, 3:22PM CDT
If you've been feeling like drugmaker mergers and acquisitions have been busting out all over the place this year, professional-services firm PricewaterhouseCoopers has the numbers to back you up. In its second-quarter report on the subject, released...

RXi Pharmaceuticals (RXII) Jumps: Stock Moves 11.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 8:46AM CDT
RXi Pharmaceuticals (RXII) was a big mover last session, with shares rising over 11% on the day.

Mallinckrodt Pharmaceuticals Releases Human Abuse Liability (HAL) Data for Investigational MNK-155, an Extended-Release Hydrocodone/Acetaminophen Combination
Business Wire - Wed Sep 03, 8:02AM CDT
Mallinckrodt (NYSE: MNK) today reported data from a Human Abuse Liability (HAL) study in which both intact and crushed MNK-155 showed lower subjective abuse-related effects than an immediate-release hydrocodone bitartrate/acetaminophen formulation (a generic form of Vicodin(R)). The data will be presented at PAINWeek 2014, a national conference on pain for frontline practitioners, in Las Vegas, Nevada September 2-6, 2014.

Mallinckrodt Pharmaceuticals to Hold Investor Briefing October 14, 2014, in New York
Business Wire - Tue Sep 02, 3:10PM CDT
Mallinckrodt plc. (NYSE: MNK), a leading global specialty pharmaceutical company, will hold an investor briefing on Tuesday, October 14, 2014, in New York City. Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, will present along with members of Mallinckrodt's senior management team. The presentation will include announcement of the company's fiscal year 2015 financial guidance.

Novo Nordisk's Ryzodeg Now in Mexico for Type II Diabetes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 2:00PM CDT
Novo Nordisk (NVO) has launched its type II diabetes treatment, Ryzodeg, in Mexico. This makes Mexico the first country where Ryzodeg is commercially available.

Cramer: What's Working, What's Not
at The Street - Tue Sep 02, 11:05AM CDT
Yep, the bets for the rest of 2014 are being placed.

Upcoming Conferences, Market Activity, Drug Approval, and Earnings Release - Research Reports on Mallinckrodt, Vertex Pharmaceuticals, Kite, Bristol-Myers Squibb and Arrowhead
PR Newswire - Fri Aug 29, 7:40AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt plc (NYSE: MNK), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Kite Pharma, Inc. (NASDAQ: KITE), Bristol-Myers Squibb Company (NYSE: BMY) and Arrowhead Research Corp. (NASDAQ: ARWR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6071-100free.

UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:40PM CDT
Actavis has filed an ANDA with the FDA seeking marketing approval for its generic version of UCB's Neupro. In response, UCB filed a lawsuit against Actavis.

Mallinckrodt Pharmaceuticals to Present Data for Investigational and Approved Extended-Release Opioid Combination Medicines at PAINWeek
Business Wire - Thu Aug 28, 8:00AM CDT
Mallinckrodt (NYSE: MNK) today announced that clinical data for its investigational opioid, MNK-155 (hydrocodone bitartrate and acetaminophen) and approved opioid combination product XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII) will be presented at PAINWeek 2014, a national conference on pain for frontline practitioners, September 2-6, in Las Vegas, Nevada.

Mallinckrodt Nears Buy Point As Sales, Earnings Rise
at Investor's Business Daily - Wed Aug 27, 5:12PM CDT
Drugmaker Mallinckrodt, bulked up by buying Questcor Pharmaceuticals in August and buoyed by its addition to the S&P 500 index, has in the past several months become much more interesting than it used to be. Mallinckrodt's (MNK) earnings fell in 2010...

Mallinckrodt (MNK) On Momo Momentum Watch Today
at The Street - Tue Aug 26, 1:56PM CDT
Trade-Ideas LLC identified Mallinckrodt (MNK) as a momo momentum candidate

Jim Cramer's 'Mad Money' Recap: Thank You, Corporate America
at The Street - Mon Aug 25, 7:00PM CDT
Corporate profits, not the Fed, are fueling ever higher stock prices, and that growth is only accelerating, Cramer says.

Jim Cramer's Top Stock Picks: PLKI MNK
at The Street - Tue Aug 26, 5:00AM CDT
Popeye's Louisiana Kitchen is a quality restaurant stock at a discount while Mallinckrodt Pharmaceuticals has the right formula for growth.

Mallinckrodt to Present at Morgan Stanley 2014 Global Healthcare Conference
Business Wire - Mon Aug 25, 3:05PM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, will present at the Morgan Stanley Global Healthcare Conference in New York on Monday, September 8, 2014. Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, will represent the company in a session scheduled to begin at 9:20 AM, Eastern Time.

Investors' Radars Failed to Catch Mallinckrodt (MNK), Has Yours? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 7:49AM CDT
One company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Mallinckrodt, the stock of which company has actually seen rising estimates over the past one month.

Lannett Updates on Digoxin Safety Issues, Expands Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 3:50PM CDT
Lannett Company, Inc.'s (LCI) shares fell after concerns rose regarding the safety of digoxin.

Ampio Shares Fall as STEP Study on Ampion Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 3:35PM CDT
Shares of Ampio Pharmaceuticals, Inc. (AMPE) declined significantly after the company announced that there will be a delay in the data analysis of the STEP Study on its candidate Ampion.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Health Net Invests $3 Million in Stockton Housing

Putting a Roof Over Stockton's Head The talk of the town in Stockton is Health Net stepping up with a $3 million investment. This isn't just dropping loose change in a jar; it's about tackling a mammoth issue—making affordable housing more than just a pipe dream for 75 families. Community-driven, they say. What a cozy way to paint a picture of bridging that brutal gap...

Partner Joins Yardi ICN, Boosting Data Quality for Clients

Strategic Alliances in Real Estate Data When Partner Engineering and Science, Inc. says they're hooking up with the Yardi Independent Consultant Network (ICN), that's not just some boardroom handshake. It's a play that could shake up data services in the real estate game. Look, there's plenty of chatter about digitizing property management, but without killer data, those...

Dyania, NVIDIA Team Up: AI Transforming Patient Care

Revving up efficiency in healthcare usually sounds like pie-in-the-sky talk, but every now and again, an innovation comes along that really stirs the pot. Enter Dyania Health's Synapsis AI, a clinical reasoning AI, teaming with NVIDIA's robust computing infrastructure. They're setting out to make sense of massive amounts of patient data, securely tucked behind a...

D-Wave's 9.5% Drop: Fraud Lawsuit Raises Investor Ire

Shockwaves from D-Wave's Earnings Call August wasn't exactly a banner month for D-Wave Quantum, Inc. as their stock went down like a lead balloon following a lackluster earnings report. If you've ever had any skin in the game, you'd know a 9.5% drop isn't just peanuts—it's the equivalent of watching your prized racehorse stumble at the first hurdle. The financials spoke...

Euroandinos Paita Closes Consent for 2037 Notes

Port Strategy and Financial Implications Terminales Portuarios Euroandinos Paita S.A., nestled in the Peruvian transport sector, has been tight-rope walking through its debt landscape. Announcing a successful consent solicitation on November 13, 2026, they've taken a significant step towards reconfiguring their long-term financing game. This puppet show of paperwork...

PenFed Fuels Aggie Spirit with Blackout Game Activation

A Different Kind of Game Day Experience Ah, there's nothing quite like the vibrancy of a Texas A&M game day, especially when it's a blackout event. On November 14, fans aren't just getting the good old college football thrills; they're diving headfirst into an extravaganza, courtesy of PenFed Credit Union. You might know them as the go-to credit union for military folks,...

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Fly-E Faces Revenue Drop Amid Retail Restructuring

Downturn Despite Strategic Restructuring Today, we're diving into Fly-E Group, Inc. (NASDAQ:FLYE) and the latest shakeup in their financials—spoiler alert, it's riding a downward slope. Quarter two of fiscal 2027 didn't exactly shine a light on profitability. Net revenues slid, dropping to $2.6 million this quarter, down from $3.9 million the previous year. Tack that up...

LA Fitness ELEVATE Opens at RITHM: A New Era Dawns

Elevating Fitness at RITHM: A New Era Has Begun RD Management just dropped a new ace in Tampa Bay’s hand—LA Fitness ELEVATE at the RITHM at Uptown. They lit up the scene with this 30,000-square-foot beast of a gym, and I’ll tell you, it’s not your standard run-of-the-mill joint. When you toss twelve-and-a-half million bucks into a pot, you're aiming to lure folks...

FiEE Rockets to Profitability with 382% Revenue Surge

Big Moves in the Tech Jungle: FiEE's Comeback Let's chew the fat on FiEE, Inc., a company that's left its hardware-heavy past in the dust and grabbed the bull by the horns with fresh, AI-driven brand tech solutions. We're talking a whopping 382.1% revenue increase. Now, that's not chump change. From barely scraping $2 million last year to raking in $9.6 million just for...